MYELOFIBROSIS

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This study tests an experimental drug called INCB057643, given alone or with another drug (ruxolitinib), in people with myelofibrosis and other advanced blood cancers. The main goal is to check safety and see if it can reduce spleen size, which is often enlarged in these conditio…

This study gives continued access to the drug itacitinib for people who were already taking it in a previous study and were doing well. It includes patients with myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after a lung transplant. The goal is to …

This study looks at whether a stem cell transplant or the best non-transplant treatments work better for people with high-risk myelofibrosis, a serious bone marrow cancer. About 90 participants will choose which treatment they want, and researchers will track their survival and q…

This study tests a new drug called BMS-986158, alone or with standard treatments (ruxolitinib or fedratinib), in people with intermediate or high-risk myelofibrosis, a serious blood cancer. About 216 adults will take part to see if the drug is safe and helps shrink the spleen or …

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers, including lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and with other treatments. Researchers also want to…

This study tested whether adding the drug veliparib to standard chemotherapy helps people with advanced blood cancers like acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). About 25 adults took part. The goal was to see if the combination improved response …

This study tests whether adding a new drug (pelabresib) to the standard treatment (ruxolitinib) works better than the standard treatment alone for people with myelofibrosis, a rare bone marrow disorder. About 430 adults who have not received prior JAK inhibitor therapy will take …

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers like leukemia and lymphoma. The goal was to see if this approach could help patients survive and recover without severe side effects.…

This early-phase trial tests a new treatment for people whose blood cancer (like AML or MDS) has returned after a stem cell transplant. The treatment combines a special donor cell infusion with an immunotherapy drug (ipilimumab) to fight the cancer. The main goal is to find the s…

This study tests a vaccine called Triplex to see if it can prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV is usually harmless but can be dangerous for people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA…

This early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like leukemia and myelofibrosis. The goal is to find a safe dose that controls the disease. Sixteen adults aged 18 and older are …

This early-phase study tests a new antibody called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The main goal is to find a safe dose and check for side effects. Researchers hope the antibody can slow or stop cancer growth.

This study tests a drug called selinexor in people with myelofibrosis, a rare bone marrow disorder, whose disease has not improved enough after at least 6 months of standard JAK inhibitor therapy. About 112 participants will be randomly assigned to receive either selinexor or ano…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease. About 313 adults with various blood cancers…

This study tests an experimental drug called imetelstat against the best available treatments for people with a rare bone marrow cancer called myelofibrosis. Participants have an advanced form of the disease that no longer responds to standard therapy. The main goal is to see if …

This study tests whether adding the drug selinexor to the standard treatment ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a rare bone marrow cancer. About 353 adults with moderate-to-high risk disease who have not had prior treatment will take pa…

This study tests whether combining two drugs, ruxolitinib and thalidomide, can shrink the cancer and improve symptoms in people with myelofibrosis, a rare bone marrow disorder. About 30 adults with the disease, including those who have tried other treatments, will receive the com…

This early-phase trial tests whether giving a CMV vaccine to stem cell donors can boost the recipient's immunity after transplant. About 34 blood cancer patients receiving donor stem cells are involved. The goal is to prevent CMV viremia, a common and serious viral infection, wit…

This study follows about 40 people with intermediate- or high-risk myelofibrosis who are already taking gecacitinib from earlier trials. Researchers collect bone marrow and blood samples once a year to see if the disease and gene mutations change over time. No new treatments are …